C
221.32
0.29 (0.13%)
| Previous Close | 221.03 |
| Open | 221.09 |
| Volume | 1,323,213 |
| Avg. Volume (3M) | 1,361,465 |
| Market Cap | 6,959,696,896 |
| Price / Earnings (Forward) | 5.75 |
| Price / Sales | 0.990 |
| Price / Book | 16.48 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -35,743.71% |
| Diluted EPS (TTM) | -26.68 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 1.89% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | -191.84 M |
| Levered Free Cash Flow (TTM) | -81.87 M |
| Return on Assets (TTM) | -55.20% |
| Return on Equity (TTM) | -299.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cidara Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.9
| Analyst Consensus | -3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.90 |
|
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.12% |
| % Held by Institutions | 73.93% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 190.00 (Morgan Stanley, -14.15%) | Buy |
| Median | 147.50 (-33.35%) | |
| Low | 135.00 (Needham, -39.00%) | Buy |
| Average | 155.00 (-29.97%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 103.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 07 Nov 2025 | 135.00 (-39.00%) | Buy | 104.39 |
| RBC Capital | 07 Nov 2025 | 145.00 (-34.48%) | Buy | 104.39 |
| HC Wainwright & Co. | 21 Oct 2025 | 150.00 (-32.22%) | Buy | 103.22 |
| Morgan Stanley | 16 Oct 2025 | 190.00 (-14.15%) | Buy | 102.02 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAVARPANAH NICOLE NEGAR | - | 220.41 | -450 | -99,185 |
| Aggregate Net Quantity | -450 | |||
| Aggregate Net Value ($) | -99,185 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 220.41 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DAVARPANAH NICOLE NEGAR | Officer | 29 Dec 2025 | Disposed (-) | 450 | 220.41 | 99,185 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |